Zagotenemab (LY3303560)

Zagotenemab (LY3303560)

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Zagotenemab (LY3303560)</th>
</tr>
<tr>
<td class="label">Therapeutic</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Zagotenemab (LY3303560)</td>
<td>Eli Lilly</td>
</tr>
<tr>
<td class="label">Semorinemab</td>
<td>Roche/Genentech</td>
</tr>
<tr>
<td class="label">Tilavonemab</td>
<td>AbbVie</td>
</tr>
<tr>
<td class="label">JNJ-63742057</td>
<td>Janssen</td>
</tr>
<tr>
<td class="label">Lu AF87908</td>
<td>Lundbeck</td>
</tr>
</table>

Zagotenemab (development code LY3303560) is a humanized anti-tau monoclonal antibody developed by Eli Lilly for the treatment of Alzheimer's disease["@zagotenemab"][@zagotenemaba]. It targets early pathological conformations of tau protein and was in Phase II clinical development. The therapeutic represents a significant approach to tau-directed immunotherapy, focusing on conformational rather than sequence-specific epitopes.

Background and Rationale

Tau Pathology in Alzheimer's Disease

Zagotenemab (LY3303560)

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Zagotenemab (LY3303560)</th>
</tr>
<tr>
<td class="label">Therapeutic</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Zagotenemab (LY3303560)</td>
<td>Eli Lilly</td>
</tr>
<tr>
<td class="label">Semorinemab</td>
<td>Roche/Genentech</td>
</tr>
<tr>
<td class="label">Tilavonemab</td>
<td>AbbVie</td>
</tr>
<tr>
<td class="label">JNJ-63742057</td>
<td>Janssen</td>
</tr>
<tr>
<td class="label">Lu AF87908</td>
<td>Lundbeck</td>
</tr>
</table>

Zagotenemab (development code LY3303560) is a humanized anti-tau monoclonal antibody developed by Eli Lilly for the treatment of Alzheimer's disease["@zagotenemab"][@zagotenemaba]. It targets early pathological conformations of tau protein and was in Phase II clinical development. The therapeutic represents a significant approach to tau-directed immunotherapy, focusing on conformational rather than sequence-specific epitopes.

Background and Rationale

Tau Pathology in Alzheimer's Disease

Tau protein is a microtubule-associated protein that stabilizes neuronal axons under normal conditions. In Alzheimer's disease and related tauopathies, tau becomes hyperphosphorylated, aggregates into neurofibrillary tangles (NFTs), and spreads through connected brain regions in a characteristic pattern that correlates with clinical progression[@tau_oligomers]. The "Braak staging" system describes this spread from the entorhinal cortex to limbic regions and ultimately to isocortex as disease advances.

The tau hypothesis of AD progression proposes that pathological tau species, particularly soluble oligomers, are the primary drivers of neurotoxicity rather than the late-stage insoluble tangles. These oligomeric species are thought to propagate between neurons, seeding the aggregation of endogenous tau and driving synaptic dysfunction and neuronal loss. This mechanistic understanding created the rationale for developing antibodies that could intercept tau oligomers before they establish permanent pathology.

Rationale for Conformational Targeting

Traditional tau immunotherapy approaches have predominantly targeted specific phosphorylation sites (e.g., pThr181, pSer396) or linear epitopes. Zagotenemab took a different approach by targeting conformational epitopes that distinguish pathological tau aggregates from normal protein. The antibody was derived from the MCI-1 mouse monoclonal antibody, which specifically recognizes early tau aggregation intermediates rather than monomeric or fully fibrillar tau[@mci1_antibody].

This conformational targeting strategy addresses several limitations of epitope-specific approaches:

Mechanism of Action

Zagotenemab is designed to bind and neutralize soluble tau aggregates that represent early pathological species[@zagotenemab][@anti_tau_mechanisms]:

• Target Epitope: Conformational epitopes on early pathological tau aggregates, specifically oligomeric species and early fibrils
• Mechanism: Binds pathological tau species in the extracellular space and possibly within the CNS, neutralizing their toxic effects and potentially facilitating clearance
• Origin: Derived from the MCI-1 mouse monoclonal antibody through humanization
• Goal: Intercept tau species before they establish permanent neurofibrillary pathology and propagate to connected brain regions

Binding Characteristics

The MCI-1-derived antibody recognizes a conformational epitope present on pathological tau aggregates but not on normal monomeric tau. This specificity is crucial because:

Clinical Development

Preclinical Development

The development of zagotenemab built on extensive preclinical characterization of the MCI-1 antibody. Studies demonstrated:

• Specific binding to tau aggregates in brain tissue from AD patients
• Lack of binding to normal tau in healthy brain
• Ability to neutralize tau oligomer-induced toxicity in cellular models
• Appropriate pharmacokinetic properties for chronic dosing

Phase I Trial

First-in-human studies characterized the safety, tolerability, and pharmacokinetics of zagotenemab in healthy volunteers and patients with Alzheimer's disease[@zagotenemab].

Trial Design: Single and multiple ascending dose study in healthy adults and early AD patients

Key Findings:

• Generally well-tolerated at all dose levels tested
• Dose-proportional pharmacokinetics
• Evidence of target engagement (plasma tau elevation consistent with antibody binding)
• No dose-limiting toxicity identified

Phase II Trial (PERISCOPE-ALZ)

The Phase II PERISCOPE-ALZ trial evaluated zagotenemab in patients with early Alzheimer's disease[@zagotenemaba]:

• Enrollment: 360 participants with early AD (MCI due to AD or mild AD dementia)
• Dosing: 1,400 mg or 5,600 mg monthly intravenous doses
• Duration: 2 years (104 weeks)
• Primary Endpoint: Change from baseline on the integrated Alzheimer's Disease Rating Scale (iADRS)
• Result: Did not meet primary endpoint — no significant difference from placebo in clinical outcomes
• Biomarker Findings: Treatment caused a dose-dependent increase in plasma tau, but tau-PET was not changed
• Status: Development discontinued in October 2021

Analysis of Trial Outcomes

Why Did Zagotenemab Fail?

Several factors may have contributed to the negative PERISCOPE-ALZ results:

Biomarker Insights

The biomarker findings from PERISCOPE-ALZ are particularly informative[@biofluid_tau]:

• Plasma tau increase: Dose-dependent elevation suggests antibody successfully bound tau in the periphery
• No tau-PET change: Indicates the antibody did not meaningfully impact established brain tau pathology
• Interpretation: Peripheral sink effect may have dominated, with antibody binding plasma tau without sufficient CNS penetration to affect brain pathology

Scientific Impact and Lessons Learned

The zagotenemab program, despite its negative outcome, provided valuable insights for the tau immunotherapy field:

1. Biomarker Validation Challenges

2. Patient Selection

• Biomarker-confirmed tau pathology (positive tau-PET or CSF markers)
• Mild or pre-symptomatic disease stage
• Minimal established neurodegeneration

3. Antibody Engineering

• Engineering antibodies with enhanced brain penetration
• Using transferrin receptor-mediated uptake
• Developing smaller antibody fragments
• Combination approaches with blood-brain barrier modulators

4. Target Engagement Assays

Current Status

Zagotenemab (LY3303560) development has been discontinued following the negative Phase II PERISCOPE-ALZ trial results. The program provided insights into:

• Challenges of targeting conformational tau epitopes
• Disconnect between biomarker effects and clinical efficacy
• Importance of proper patient selection for tau immunotherapy trials
• Need for improved CNS delivery for antibody-based therapies

Comparison with Other Tau Immunotherapies

All anti-tau antibody programs have faced significant challenges, with most failing to meet primary endpoints in Phase II trials. This underscores the complexity of tau-targeted therapy and the need for alternative approaches.

Future Directions

The lessons from zagotenemab and other failed tau immunotherapy programs inform current research directions:

See Also

• [Tau Immunotherapy](/therapeutics/anti-tau-immunotherapy-programs)
• [Tau Protein](/proteins/tau)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Alzheimer's Disease Therapeutics](/therapeutics/alzheimers-disease-therapeutics)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [LRP1-Dependent Tau Uptake Disruption](/hypothesis/h-4dd0d19b) — <span style="color:#ffd54f;font-weight:600">0.53</span> · Target: LRP1

Pathway Diagram

The following diagram shows the key molecular relationships involving Zagotenemab (LY3303560) discovered through SciDEX knowledge graph analysis: